Kanishk Kumar – Hemophilia A Pipeline 2025: New Therapies Changing Patient Care
Kanishk Kumar, Digital Marketing Executive at DelveInsight Business Research LLP, posted on LinkedIn:
“Hemophilia A Pipeline 2025: New Therapies Changing Patient Care
The Hemophilia A treatment landscape is evolving fast in 2025. Researchers and companies are pushing forward gene therapies, long-acting factor replacements, and innovative prophylactic options, all aimed at improving patients’ quality of life and reducing the burden of frequent treatments.
Recent Highlights:
On 10 October 2025, Roche initiated a Phase I/II study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of NXT007 in patients with severe or moderate Hemophilia A.
On 08 October 2025, BioMarin Pharmaceutical Inc. announced a Phase III study to assess the safety and effectiveness of valoctocogene roxaparvovec in combination with prophylactic corticosteroids in patients with severe Hemophilia A.
Key companies leading the way include Roche, Chugai Pharmaceutical Co., Ltd. , Shire , Pfizer , BioMarin Pharmaceutical Inc., Sinocelltech Ltd., Bayer, Ultragenyx , Spark Therapeutics, Inc., Octapharma, APCINTEX LIMITED , Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Expression Therapeutics, Inc., CSL and others.”
See the full Hemophilia A Pipeline 2025 report and track the therapies shaping the future here.
Stay updated with Hemostasis Today.
-
May 12, 2026, 14:01Moses Wasswa: Tackling Sickle Cell Disease in Uganda
-
May 12, 2026, 13:58Arun Chervu: Most DVT Patients Do Well on Anticoagulation Alone
-
May 12, 2026, 13:49Shashank Joshi: Antiphospholipid Antibodies and Risk of Thrombotic Cardiovascular Events
-
May 12, 2026, 13:44Hayley Evans: Variability in Perioperative TXA Practice Despite Strong Evidence
-
May 12, 2026, 11:13Matteo Foschi: Grateful To Be Selected for The WSO Future Stroke Leaders Programme
-
May 12, 2026, 11:05Omid Seidizadeh: Strategies to Guide The 2nd 100 years of VWD Care and Research
-
May 12, 2026, 11:01Kate Scrivener: The Big Picture of Exercise Trials to Prevent Falls After Stroke
-
May 12, 2026, 10:39Rucha Patil: Our ”Factor VIII Inhibitor Point-of-Care Diagnostic” Is Successfully Transferred at Science-Tech
-
May 12, 2026, 10:26Fabrice Cognasse: The EFS Is First and Foremost Part of a Medical Discipline – Transfusion